The first experience of immunotherapy application of ipilimumab in combination with chemotherapy of small-cell lung cancer in the Russian population. Analysis of the combined data of two centers, participating in the multicenter randomized phase III study СА 184-156

Introduction. Patients with advanced small cell lung cancer (SCLC) have an extremely poor prognosis on the background of standard chemotherapy combination of etoposide and platinum-based drugs. In a randomized, double-blind of СА184-156 phase III study, the efficacy and safety of ipilimumab (immune...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: A E Kuzminov, V A Gorbunova, E V Poddubskaya, S G Bagrova, M P Baranova, K K Laktionov
Médium: Artigo
Jazyk:Russo
Vydáno: IP Habib O.N. 2018-09-01
Edice:Современная онкология
Témata:
small cell lung cancer
ipilimumab
On-line přístup:https://modernonco.orscience.ru/1815-1434/article/viewFile/29557/pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky